Literature DB >> 20938663

Iron overload in MDS-pathophysiology, diagnosis, and complications.

Norbert Gattermann1, Eliezer A Rachmilewitz.   

Abstract

Many patients with myelodysplastic syndromes (MDS) become dependent on blood transfusions and develop transfusional iron overload, which is exacerbated by increased absorption of dietary iron in response to ineffective erythropoiesis. However, it is uncertain whether there is an association among iron accumulation, clinical complications, and decreased likelihood of survival in MDS patients. Here, we discuss our current understanding of the effects of transfusion dependency and iron overload in MDS, indicate our knowledge gaps, and suggest that particular emphasis should be placed on further characterizing the role of redox-active forms of labile iron, which may be as important as the total iron burden.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20938663     DOI: 10.1007/s00277-010-1091-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  26 in total

1.  Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.

Authors:  Yanni Hua; Chaomeng Wang; Huijuan Jiang; Yihao Wang; Chunyan Liu; Lijuan Li; Hui Liu; Zonghong Shao; Rong Fu
Journal:  Int J Hematol       Date:  2017-04-12       Impact factor: 2.490

Review 2.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

3.  Oxidative stress and labile plasmatic iron in anemic patients following blood therapy.

Authors:  Marília Sabo Fernandes; Tatiana Tamborena Rissi; Luisa Zuravski; Juliana Mezzomo; Carmen Regla Vargas; Vanderlei Folmer; Félix Alexandre Antunes Soares; Vanusa Manfredini; Mushtaq Ahmed; Robson Luiz Puntel
Journal:  World J Exp Med       Date:  2014-08-20

Review 4.  Chelation therapy for iron overload: nursing practice implications.

Authors:  Ellen J Eckes
Journal:  J Infus Nurs       Date:  2011 Nov-Dec

5.  Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study.

Authors:  Jong Wook Lee; Sung-Soo Yoon; Zhi Xiang Shen; Arnold Ganser; Hui-Chi Hsu; Ali El-Ali; Dany Habr; Nicolas Martin; John B Porter
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

6.  Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.

Authors:  Florian Nolte; Holger Nückel; Burkhard Schmidt; Thomas Geer; Oleg Rubanov; Holger Hebart; Andrea Jarisch; Stefan Albrecht; Christiane Johr; Christiane Schumann; Wolf-Karsten Hofmann
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-14       Impact factor: 4.553

Review 7.  Physiology and pathophysiology of iron in hemoglobin-associated diseases.

Authors:  Thomas D Coates
Journal:  Free Radic Biol Med       Date:  2014-04-12       Impact factor: 7.376

8.  Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.

Authors:  Rui Cui; Robert Peter Gale; Guoqing Zhu; Zefeng Xu; Tiejun Qin; Yue Zhang; Gang Huang; Bing Li; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Zhijian Xiao
Journal:  Leuk Res       Date:  2014-02-10       Impact factor: 3.156

9.  The effects of secondary iron overload and iron chelation on a radiation-induced acute myeloid leukemia mouse model.

Authors:  Lap Shu Alan Chan; Lilly ChunHong Gu; Richard A Wells
Journal:  BMC Cancer       Date:  2021-05-06       Impact factor: 4.430

10.  Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.

Authors:  Norbert Gattermann; Andrea Jarisch; Rudolf Schlag; Klaus Blumenstengel; Mariele Goebeler; Matthias Groschek; Christoph Losem; Maria Procaccianti; Alexia Junkes; Oliver Leismann; Ulrich Germing
Journal:  Eur J Haematol       Date:  2011-11-24       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.